e-learning
resources
Stockholm 2007
Monday 17.09.2007
Delivering respiratory care: the challenges for primary care
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Exhaled nitric oxide as the sole determinant of therapy in all obstructive patients in a primary care setting: long-lasting effects on health related quality of life
J. A. Irvine, L. E. Gustafsson, O. Zetterström (Limassol, Cyprus; Stockholm, Linköping, Sweden)
Source:
Annual Congress 2007 - Delivering respiratory care: the challenges for primary care
Session:
Delivering respiratory care: the challenges for primary care
Session type:
Oral Presentation
Number:
1787
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. A. Irvine, L. E. Gustafsson, O. Zetterström (Limassol, Cyprus; Stockholm, Linköping, Sweden). Exhaled nitric oxide as the sole determinant of therapy in all obstructive patients in a primary care setting: long-lasting effects on health related quality of life. Eur Respir J 2007; 30: Suppl. 51, 1787
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Exhaled nitric oxide in respiratory diseases other than asthma
Source: Eur Respir Monogr 2010; 49: 45-55
Year: 2010
Exhaled nitric oxide in diagnosis and management of respiratory diseases
Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases
Year: 2013
Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function
Source: Eur Respir J 2001; 17: 934-938
Year: 2001
The impact of fractional exhaled nitric oxide (FeNO) measurement on treatment decision making in the specialist care of established asthma
Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases
Year: 2013
Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD
Source: Eur Respir J 2010; 35: 72-78
Year: 2010
Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma
Source: Eur Respir J 2008; 32: 344-349
Year: 2008
Impact of preventing exacerbations on deterioration of health status in COPD
Source: Eur Respir J 2004; 23: 698-702
Year: 2004
Exhaled nitric oxide in childhood asthma
Source: Annual Congress 2006 - Paediatric Respiratory Research Award
Year: 2006
Nitric oxide and oxygen inhalation during exercise in patients with chronic obstructive lung disease (COPD) and secondary pulmonary hypertension (PH)
Source: Eur Respir J 2001; 18: Suppl. 33, 83s
Year: 2001
The impact of treatment of chronic obstructive pulmonary disease (COPD) on functional status and quality of life of patients
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012
Use of exhaled nitric oxide measurements to guide treatment in chronic asthma
Source: Annual Congress 2006 - Scientific year in review
Year: 2006
Is Fractional exhaled nitric oxide (FeNO) test reliable in the differentiation of chronic obstructive pulmonary disease (COPD) and ACOS (asthma-COPD overlap syndrome)?
Source: International Congress 2017 – Lung function testing in different patient categories
Year: 2017
Interpreting thresholds for a clinically significant change in health status in asthma and COPD
Source: Eur Respir J 2002; 19: 398-404
Year: 2002
Does treatment guided by exhaled nitric oxide fraction improve outcomes in subgroups of children with asthma?
Source: Eur Respir J, 55 (5) 1901879; 10.1183/13993003.01879-2019
Year: 2020
Differential assessment of airway inflammation in chronic obstructive pulmonary disease (COPD) by measurements of exhaled nitric oxide (NO) derived from peripheral
vs.
central airways
Source: Eur Respir J 2003; 22: Suppl. 45, 279s
Year: 2003
Integrated disease management improves long-term quality of life in primary care COPD patients
Source: Annual Congress 2007 - Management of COPD: pushing forward the boundaries in primary care
Year: 2007
Is exhaled nitric oxide (eNO) an indipendent outcome measure in chronic stable asthma?
Source: Eur Respir J 2002; 20: Suppl. 38, 196s
Year: 2002
Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma
Source: Eur Respir J 2010; 35: 1221-1227
Year: 2010
The role of inflammatory biomarkers and health related quality of life questionnaires in distinction of exacerbation and stable chronic obstructive pulmonary diseases
Source: International Congress 2014 – Markers
Year: 2014
Usefulness of fraction of exhaled nitric oxide and asthma management questionnaires in predicting a future risk of asthma exacerbation
Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept